Dr. rer. nat. Katja Schmidt



IgA displays site- and subclass-specific glycoform differences despite equal glycoenzyme expression (2025) Falck D, Sokolova M, Koeleman CA, Irumva V, Kirchner P, Schulz S, Schmidt K, et al. Journal article Serum extracellular matrix biomarkers in rheumatoid arthritis, psoriatic arthritis and psoriasis and their association with hand function (2025) Port H, Coppers B, Tragl S, Manger E, Niemiec LM, Bayat S, Simon D, et al. Journal article, Original article Coronavirus replicase epitopes induce cross-reactive CD8 T cell responses in SARS-CoV-2-naive people with HIV-1 (2025) Schmidt K, Geißler P, Schuster EM, Schülein C, Harrer E, Schönau V, Luber M, et al. Journal article Protumoral lipid droplet-loaded macrophages are enriched in human glioblastoma and can be therapeutically targeted (2024) Governa V, de Oliveira KG, Bång-Rudenstam A, Offer S, Cerezo-Magaña M, Li J, Beyer S, et al. Journal article Tixagevimab/cilgavimab for the prevention of COVID-19 in vaccine-refractory patients with autoimmune diseases: a prospective cohort study. (2024) Minopoulou I, Tascilar K, Corte G, Mutlu MY, Schmidt K, Bohr D, Hartmann F, et al. Journal article Cellular and humoral immune responses to SARS-CoV-2 vaccination in patients after CD19.CAR T-cell therapy (2023) Reimann H, Kremer A, Blumenberg V, Schmidt K, Aigner M, Jacobs B, Eisenhauer N, et al. Journal article, Letter Definition of a New HLA B*52-Restricted Rev CTL Epitope Targeted by an HIV-1-Infected Controller (2023) El Kenz B, Schmidt K, Ogungbemi-Alt VK, Bergmann S, Steininger P, Korn K, Spriewald B, et al. Journal article Detection of pre-existing neutralizing antibodies against Ad26 in HIV-1-infected individuals not responding to the Ad26.COV2.S vaccine (2023) Schmidt K, Harrer E, Schönau V, Simon D, Kleyer A, Steininger P, Korn K, et al. Journal article Sars-Cov-2 Vaccine-Induced Cellular and Humoral Immunity in Patients after CD19.CAR-T Cell Therapy (2022) Reimann H, Kremer A, Blumenberg V, Schmidt K, Aigner M, Kremer A, Tenbusch M, et al. Conference contribution PRE-EXPOSURE PROPHYLAXIS FOR SARS-COV-2 INFECTION WITH SUBCUTANEOUS CASIRIVIMAB/IMDEVIMAB IN PATIENTS WITH IMMUNE MEDIATED INFLAMMATORY DISEASES. (2022) Fagni F, Schmidt K, Bohr D, Valor L, Hartmann F, Tascilar K, Manger K, et al. Conference contribution